UNSPSC 51112803: Ospemifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C24H23ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0P231ILBK, chemically known as 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol but more generally known as ospemifene, which bears US NIH Compound Identifier 3036505. European Medicines Agency schedules Ospemifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33020.

UNSPSC 51112803 Ospemifene is a Commodity code covering a specific pharmaceutical product—a selective estrogen receptor modulator indicated for postmenopausal vaginal atrophy. State and local governments procure ospemifene primarily through state Medicaid programs and employee health plans that manage pharmaceutical benefits for beneficiaries. The work involved is straightforward product acquisition: health plans and state agencies source the drug through established pharmaceutical supply channels, negotiate pricing with manufacturers or wholesalers, and manage formulary placement and patient access. Issuing bodies for ospemifene solicitations are predominantly state health and human services departments managing Medicaid programs, though employee benefit programs for state and local workers and retirees may also seek the product through cooperative purchasing or direct-contracting initiatives.

The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that contemplates direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers. This exploratory procurement vehicle signals Texas HHS interest in restructuring how the state sources medications—including specialty pharmaceuticals like ospemifene—outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler intermediaries. The RFI requests vendor experience with direct contracting for self-insured employers and government health plans, flexibility on negotiated net pricing models, and capability to implement outcomes-based agreements. Geographic activity is limited to Texas based on current records; no other states show recent ospemifene-specific solicitations at this time. The absence of formal award amounts, site visit requirements, or set-aside designations in the RFI reflects its preliminary market-intelligence purpose before a formal RFP.